

Human Menopausal Gonadotropin - Purified

Catalog No.:	PA1192
Quantity:	1 mg
Concentration:	1.0 mg/ml
Species:	Human
Source:	Urine, Urine of post-menopausal women.
Format:	State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: >98% Greater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel. Buffer System: Lyophilized from a concentrated solution in water containing no additives. Reconstitution: It is recommended to reconstitute the lyophilized hMG in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Description:	hMG is produced from a sterile preparation of placental glucoprotein urine of post-menopausal women. The hMG is purified by proprietary chromatographic techniques. Biological Activity: hMG conforms the following activities: 100 IU/mg of FSH and 100IU/mg LH.
Add. Information:	Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm . 2. Analysis by RP-HPLC, using a standard solution of hMG as a Reference Standard. Free of: HbsAg, Hepatitis B surface antigen and antibodies to HIV, Hepatitis C and HCV.
Storage:	Lyophilized hMG although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution hMG should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.
General Readings:	1. Lin YH, Seow KM, Chen HJ, Huang LW, Hwang JL, Tzeng CR. Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol. Gynecol Endocrinol. 2007 Jan;23(1):45-9. PubMed PMID: 17484512. 2. Zhang HQ, Yan B, Zhao HX, Gu DY, Jia XF, Cao L, et al. Effect of traditional Chinese herbs combined with low dose human menopausal gonadotropin applied in frozen-thawed embryo transfer. Chin J Integr Med. 2006 Dec;12(4):244-9. PubMed PMID: 17361518. 3. Lin YH, Hwang JL, Seow KM, Huang LW, Hsieh BC, Tzeng CR. Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and busarelin long protocol--a randomized study. Gynecol Endocrinol. 2006 Jun;22(6):297-302. PubMed PMID: 16785154. 4. Zech NH, Netzbandt P, Zech H. Development of severe ovarian hyperstimulation

syndrome after inadvertent stimulation with a gonadotropin-releasing hormone agonist and human menopausal gonadotropin in a pre-existing early pregnancy. Fertil Steril. 2005 Dec;84(6):1745. PubMed PMID: 16359980.

5. Keye WR, Webster B, Dickey R, Somkuti S, Crain J, Scobey MJ. Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization. Reprod Biol Endocrinol. 2005 Nov 9;3:62. PubMed PMID: 16280073.

6. Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecol Endocrinol 2005 Mar;20(3):161-9